EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells

被引:249
作者
Riggi, Nicolo [1 ]
Suva, Mario-Luca [1 ]
Suva, Domizio [3 ]
Cironi, Luisa [1 ]
Provero, Paolo [4 ]
Tercier, Stephane [2 ]
Joseph, Jean-Marc [2 ]
Stehle, Jean-Christophe [1 ]
Baumer, Karine [1 ]
Kindler, Vincent [3 ]
Stamenkovic, Ivan [1 ]
机构
[1] Univ Lausanne, Inst Pathol, Div Expt Pathol, Lausanne, Switzerland
[2] Univ Lausanne, Dept Pediat Surg, Lausanne, Switzerland
[3] Univ Geneva, Dept Orthoped, Geneva, Switzerland
[4] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy
关键词
D O I
10.1158/0008-5472.CAN-07-1761
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ewing's sarcoma family tumors (ESFT) express the EWS-FLI-1 fusion gene generated by the chromosomal translocation t(11;22)(q24;q12). Expression of the EWS-FLI-1 fusion protein in a permissive cellular environment is believed to play a key role in ESFT pathogenesis. However, EWS-FLI-1 induces growth arrest or apoptosis in differentiated primary cells, and the identity of permissive primary human cells that can support its expression and function has until now remained elusive. Here we show that expression of EWS-FLI-1 in human mesenchymal stem cells (hMSC) is not only stably maintained without inhibiting proliferation but also induces a gene expression profile bearing striking similarity to that of ESFT, including genes that are among the highest ESFT discriminators. Expression of EWS-FLI-1 in hMSCs may recapitulate the initial steps of Ewing's sarcoma development, allowing identification of genes that play an important role early in its pathogenesis. Among relevant candidate transcripts induced by EWS-FLI-1 in hMSCs, we found the polycomb group gene EZH2, which we show to play a critical role in Ewing's sarcoma growth. These observations are consistent with our recent findings using mouse mesenchymal progenitor cells and provide compelling evidence that hMSCs are candidate cells of origin of ESFT.
引用
收藏
页码:2176 / 2185
页数:10
相关论文
共 50 条
[1]   Gene expression profiling of human sarcomas: Insights into sarcoma biology [J].
Baird, K ;
Davis, S ;
Antonescu, CR ;
Harper, UL ;
Walker, RL ;
Chen, YD ;
Glatfelter, AA ;
Duray, PH ;
Meltzer, PS .
CANCER RESEARCH, 2005, 65 (20) :9226-9235
[2]   Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions [J].
Bracken, AP ;
Dietrich, N ;
Pasini, D ;
Hansen, KH ;
Helin, K .
GENES & DEVELOPMENT, 2006, 20 (09) :1123-1136
[3]   EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].
Adrian P. Bracken ;
Diego Pasini ;
Maria Capra ;
Elena Prosperini ;
Elena Colli ;
Kristian Helin .
The EMBO Journal, 2003, 22 (20) :5323-5335
[4]   Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments [J].
Breitling, R ;
Armengaud, P ;
Amtmann, A ;
Herzyk, P .
FEBS LETTERS, 2004, 573 (1-3) :83-92
[5]   The Polycomb EA2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation [J].
Caretti, G ;
Di Padova, M ;
Micales, B ;
Lyons, GE ;
Sartorelli, V .
GENES & DEVELOPMENT, 2004, 18 (21) :2627-2638
[6]   The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells [J].
Codrington, R ;
Pannell, R ;
Forster, A ;
Drynan, LF ;
Daser, A ;
Lobato, N ;
Metzler, M ;
Rabbitts, TH .
PLOS BIOLOGY, 2005, 3 (08) :1459-1466
[7]   GENE FUSION WITH AN ETS DNA-BINDING DOMAIN CAUSED BY CHROMOSOME-TRANSLOCATION IN HUMAN TUMORS [J].
DELATTRE, O ;
ZUCMAN, J ;
PLOUGASTEL, B ;
DESMAZE, C ;
MELOT, T ;
PETER, M ;
KOVAR, H ;
JOUBERT, I ;
DEJONG, P ;
ROULEAU, G ;
AURIAS, A ;
THOMAS, G .
NATURE, 1992, 359 (6391) :162-165
[8]  
Deneen B, 2003, CANCER RES, V63, P4268
[9]   Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation [J].
Deneen, B ;
Denny, CT .
ONCOGENE, 2001, 20 (46) :6731-6741
[10]   Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast [J].
Ding, Lei ;
Kleer, Celina G. .
CANCER RESEARCH, 2006, 66 (19) :9352-9355